RecruitingPhase 2

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

United States60 participantsStarted 2025-10-28

Plain-language summary

The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Received for ≥ 6 months prior to screening
✓. Receiving a once-monthly regimen (approximately every 4 weeks). Note: participants on stable regimens of other durations (for example, every 3 or 6 weeks) are not eligible

What they're measuring

Percentage Change From Baseline in Serum IGF-1 Level at Week 15

Timeframe: Baseline, Week 15

Trial details

NCT IDNCT07037420

SponsorAlexion Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-01-08

Contact for this trial

Alexion Pharmaceuticals, Inc. (Sponsor)

1-855-752-2356 clinicaltrials@alexion.com

View on ClinicalTrials.gov More Acromegaly trials